Abstract
Zanubrutinib (Brukinsa (R)), an orally-administered Bruton tyrosine kinase (BTK) inhibitor, is being developed by BeiGene for the treatment of B-cell ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
